Astrana Health stock
ASTHNASDAQAstrana Health, Inc., HealthcareISIN US03763A2078
54Score 54 out of 100, Neutral
Price and trend
50 / 100
Price history
+35% in one yearThe chart shows daily closes over 18 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 7.3% below it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 29).
The price is 36% below its 52-week high. Largest decline in 18 years: 99% (April 2009 to July 2009).
Chart figures for advanced users
- SMA 50$36.53
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$34.26
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)29
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.16
- The lowest closing price of the last twelve months.
- Resistance$49.81
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Astrana Health, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $1.58B, is number 36 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.18B (up 56.4% year on year) and earnings of $22.49M (down 47.9%).
- For fiscal 2026, analysts expect on average revenue of $3.97B (up 24.9%) and adjusted earnings per share of $1.32 (up 187.4%).
Show more
- MEQIRI Score 54 out of 100 (Neutral): rank 341 of 714 in Healthcare, median 53.
- Our model puts fair value at $74.90, with the price 56% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 35.9% a year since 2020, Medical (Care Facilities) median 9.2%.Growth 75
- Earnings turn into cashFree cash flow 308% of earnings over the last 12 months.Fundamentals 73
- Analysts expect strong earnings growthUp 27.8% a year through 2028 (estimates from 5 analysts).Growth 75
Weaknesses
- DilutionShare count up 34% since 2020.Capital allocation 31
- Margin fallingOperating margin 2.5%, average of the prior years 6.1% (to 2024).Profitability 29
- Interest barely coveredOperating profit covers interest only 1.8 times.Stability 34
Its standout strengths are valuation and growth, while capital allocation and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 53 to 54.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price far below its 52-week high
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $49.93 and expensive above $149.80 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $60.93, at 7.8% it would be $95.99.
Possible value trap: looks cheap, but high risk.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 35.1% on the twelve months before. Up to 2020 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 35.9% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 9%, operating 2%, net 1%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 109 days
- Last reported
- 5 Nov 2026EPS reported $0.71 (expected $0.46)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 6.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $1.32−6.2%
- Revenue
- $3.97B−0.2%
- Earnings per share
- $1.93−2.7%
- Revenue
- $4.38B−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −0.2%2026 adjusted EBITDA guidance raised to $255 to $280 million; revenue guidance of $3.8 to $4.1 billion and free cash flow guidance of $105 to $132.5 million reaffirmed.
“Accordingly, we are reaffirming our full year revenue guidance of $3.8 billion-$4.1 billion, as well as our free cash flow guidance of $105 million-$132.5 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Astrana Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 54
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- AttendoATT.ST $1.87B65
- Healthcare Services GroupHCSG $1.7B70
- Sonida Senior LivingSNDA $1.67B32
- AmbeaAMBEA.ST $1.64B70
- U.S. Physical TherapyUSPH $1.49B55
- AMN Healthcare ServicesAMN $1.47B65
- Aevis VictoriaAEVS.SW $1.45B34
- ClarianeCLARI.PA $1.37B39
ETFs that hold Astrana Health
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.15% | 0.40% | €1.49B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.10% | 0.30% | €2.28B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €944.34M |
Show 5 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.